Pharmacology Quiz: Rate Vs Rhythm Control

20 questions · exam conditions

0:00

Rate Vs Rhythm ControlQuestion 1 of 20

A 66-year-old female with symptomatic persistent atrial fibrillation and a history of hypertension with left ventricular hypertrophy is being considered for initiation of dofetilide therapy.

Which of the following is the most critical monitoring requirement during the initiation of dofetilide to ensure patient safety?

Inpatient telemetry with measurement of the QTc interval at baseline and after each dose for a minimum of 3 days.

Weekly measurement of serum potassium and magnesium levels for the first month of therapy.

Baseline and annual pulmonary function tests to screen for interstitial lung disease.

Ophthalmologic examination including a slit-lamp exam to check for corneal microdeposits.

← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Rate Vs Rhythm Control

Practice Rate Vs Rhythm Control in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Rate Vs Rhythm Control, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 66-year-old female with symptomatic persistent atrial fibrillation and a history of hypertension with left ventricular hypertrophy is being considered for initiation of dofetilide therapy.

Which of the following is the most critical monitoring requirement during the initiation of dofetilide to ensure patient safety?

Inpatient telemetry with measurement of the QTc interval at baseline and after each dose for a minimum of 3 days. (correct answer)
Weekly measurement of serum potassium and magnesium levels for the first month of therapy.
Baseline and annual pulmonary function tests to screen for interstitial lung disease.
Ophthalmologic examination including a slit-lamp exam to check for corneal microdeposits.

Explanation: Dofetilide is a pure Class III antiarrhythmic that works by blocking the rapid component of the delayed rectifier potassium current (I_Kr). This action prolongs the QT interval and carries a significant, dose-dependent risk of Torsades de Pointes (TdP). To mitigate this risk, initiation of dofetilide requires hospitalization for a minimum of 3 days for continuous telemetry and serial QTc interval monitoring. The dose is adjusted based on the QTc response and renal function. While electrolyte monitoring (B) is important, the intensive ECG monitoring is the most critical step. Pulmonary toxicity (C) and corneal microdeposits (D) are characteristic side effects of amiodarone, not dofetilide.

Question 2

A patient with heart failure (EF 35%) is receiving digoxin for rate control of atrial fibrillation. How does digoxin's mechanism of action for rate control fundamentally differ from that of a beta-blocker like metoprolol?

Digoxin directly blocks calcium channels in the AV node, while metoprolol blocks sodium channels.
Digoxin increases vagal tone to the AV node, while metoprolol blocks sympathetic stimulation of the AV node. (correct answer)
Digoxin primarily acts by shortening the atrial refractory period, while metoprolol prolongs it.
Digoxin is a positive inotrope via Na+/K+ ATPase inhibition, while metoprolol is a negative chronotrope via beta-1 blockade.

Explanation: Both digoxin and metoprolol slow conduction through the AV node, but through different autonomic pathways. Digoxin's primary rate-controlling effect is parasympathomimetic; it increases vagal (parasympathetic) tone, which slows AV conduction. Metoprolol is a beta-1 adrenergic antagonist, blocking the effects of the sympathetic nervous system on the AV node. While statement D is true regarding their mechanisms for inotropy/chronotropy, it doesn't fully capture the key difference in their rate control mechanism at the AV node. Digoxin does not directly block calcium channels (that's a CCB). Neither drug's primary rate control mechanism is via sodium channel blockade or altering the atrial refractory period.

Question 3

A clinical pharmacist is reviewing the results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial with a medical resident. The trial compared outcomes between rate control and rhythm control strategies in patients with atrial fibrillation.

Which statement accurately reflects the primary findings of the AFFIRM trial and its impact on clinical practice?

Rhythm control was superior to rate control in reducing the incidence of ischemic stroke.
Rate control resulted in a higher all-cause mortality rate compared to the rhythm control strategy.
A strategy of rhythm control did not show a survival benefit over a rate control strategy. (correct answer)
Patients in the rhythm control arm had fewer hospitalizations and adverse drug events.

Explanation: The landmark AFFIRM trial found no significant difference in all-cause mortality between the rate control and rhythm control strategies. This finding shifted clinical practice towards favoring rate control as an initial strategy for many patients, especially those who are older and less symptomatic. Rhythm control was not superior in reducing stroke (anticoagulation is key for this, regardless of strategy). In fact, the rhythm control arm had a trend towards higher mortality and was associated with more hospitalizations and adverse drug events, likely due to the proarrhythmic and extra-cardiac toxicities of the antiarrhythmic drugs used.

Question 4

The RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) trial compared lenient rate control (resting heart rate <110 bpm) with strict rate control (resting heart rate <80 bpm) in patients with permanent atrial fibrillation.

Based on the findings of the RACE II trial, for which of the following patients would a lenient rate control strategy be most appropriate?

A 55-year-old patient with newly diagnosed HFrEF who is highly symptomatic from palpitations.
A 78-year-old patient with preserved EF who is asymptomatic and has a baseline resting heart rate of 105 bpm. (correct answer)
A 62-year-old patient being treated with dofetilide for rhythm control who experiences a relapse into atrial fibrillation.
A 45-year-old patient with paroxysmal atrial fibrillation who uses a 'pill-in-the-pocket' strategy.

Explanation: The RACE II trial demonstrated that lenient rate control was non-inferior to strict rate control for the primary cardiovascular outcome in patients with permanent atrial fibrillation, provided they had preserved EF and were largely asymptomatic. Therefore, the 78-year-old asymptomatic patient is an ideal candidate. In a highly symptomatic HFrEF patient (A), stricter rate control is often necessary to improve symptoms and hemodynamics. Patients C and D are on rhythm control strategies, so the concept of lenient vs. strict rate control targets for permanent AF is not directly applicable.

Question 5

A pharmacist is explaining why amiodarone is sometimes used for difficult-to-control ventricular rates in atrial fibrillation, even though it is primarily considered a rhythm control agent.

Which property of amiodarone contributes most significantly to its utility as a rate-controlling agent?

Its potent Class III antiarrhythmic activity, which prolongs the QT interval.
Its Class I effect, which involves moderate sodium channel blockade.
Its non-competitive beta-adrenergic and calcium channel blocking effects. (correct answer)
Its ability to inhibit the peripheral conversion of T4 to T3.

Explanation: Amiodarone is unique in that it possesses properties of all four Vaughn-Williams classes. Its utility in rate control stems from its Class II (non-competitive beta-blockade) and Class IV (calcium channel blockade) effects. These actions slow conduction through the AV node and suppress its automaticity, thereby reducing the ventricular response rate in atrial fibrillation. While its Class III (potassium channel blockade) and Class I (sodium channel blockade) effects are crucial for its rhythm control properties, they do not directly control the ventricular rate. Its effects on thyroid hormone do not contribute to rate control.

Question 6

Which statement accurately reflects the primary findings of the AFFIRM trial and its impact on clinical practice?

Rhythm control was superior to rate control in reducing the incidence of ischemic stroke.
Rate control resulted in a higher all-cause mortality rate compared to the rhythm control strategy.
A strategy of rhythm control did not show a survival benefit over a rate control strategy. (correct answer)
Patients in the rhythm control arm had fewer hospitalizations and adverse drug events.

Question 7

A patient with new-onset atrial fibrillation of 24 hours duration and no structural heart disease is to undergo pharmacological cardioversion. Which mechanism of action is primarily responsible for the efficacy of flecainide in this setting?

Prolongation of the action potential duration and refractory period in atrial tissue.
Potent blockade of fast inward sodium channels, markedly slowing conduction velocity in the atria. (correct answer)
Slowing of the sinoatrial node firing rate and conduction through the atrioventricular node.
Blockade of beta-adrenergic receptors, reducing catecholamine-induced atrial ectopy.

Explanation: Flecainide is a Class Ic antiarrhythmic drug. Its primary mechanism is potent blockade of fast sodium channels (I_Na), which leads to a marked decrease in the rate of rise of the action potential (Phase 0 depression) and a significant slowing of conduction velocity in the His-Purkinje system and atrial/ventricular myocardium. This slowing of conduction is critical for terminating reentrant circuits responsible for atrial fibrillation. Prolonging action potential duration (A) is the mechanism of Class III agents (e.g., amiodarone, dofetilide). Slowing SA/AV nodal conduction (C) is a primary effect of beta-blockers and non-dihydropyridine calcium channel blockers used for rate control. Beta-blockade (D) is the mechanism of Class II agents.

Question 8

A 50-year-old female with infrequent but highly symptomatic episodes of paroxysmal atrial fibrillation is being considered for a 'pill-in-the-pocket' rhythm control strategy. She has a normal echocardiogram and a resting ECG showing sinus rhythm with no abnormalities.

Which of the following patient characteristics would be a contraindication to the 'pill-in-the-pocket' approach with flecainide or propafenone?

History of well-controlled hypertension.
Concomitant use of a proton-pump inhibitor.
Presence of a prolonged PR interval on resting ECG. (correct answer)
Infrequent episodes occurring less than once per month.

Explanation: The 'pill-in-the-pocket' strategy involves self-administration of a single oral dose of an antiarrhythmic (typically flecainide or propafenone) at the onset of symptoms. It is reserved for patients with structurally normal hearts and infrequent episodes. A key contraindication is evidence of underlying sinus or AV nodal dysfunction, such as a prolonged PR interval, which indicates a first-degree AV block. Class Ic agents slow AV nodal conduction and can precipitate a higher-degree block. Well-controlled hypertension is not an absolute contraindication if there is no left ventricular hypertrophy. Use of a PPI is irrelevant. Infrequent episodes are an indication for, not a contraindication to, this strategy.

Question 9

A 77-year-old female with permanent atrial fibrillation and HFrEF (EF 25%) is on digoxin 125 mcg daily for rate control, in addition to carvedilol and an ACE inhibitor. She is started on amiodarone for management of ventricular tachycardia. Two weeks later, she presents with nausea, visual disturbances (yellow halos), and confusion.

The patient's new symptoms are most likely due to a drug-drug interaction that leads to which of the following changes?

Amiodarone inhibiting the renal clearance of digoxin.
Digoxin displacing amiodarone from plasma protein binding sites.
Amiodarone inducing the metabolism of digoxin via CYP3A4.
Amiodarone inhibiting P-glycoprotein, reducing digoxin efflux and excretion. (correct answer)

Explanation: The patient is presenting with classic signs of digoxin toxicity. Amiodarone is a well-known inhibitor of P-glycoprotein (P-gp), an efflux transporter protein found in the intestines, kidneys, and other tissues. Digoxin is a substrate for P-gp. By inhibiting P-gp, amiodarone reduces the intestinal efflux and renal excretion of digoxin, leading to a significant increase (often 50-100%) in its serum concentration. It is standard practice to reduce the digoxin dose by 30-50% when initiating amiodarone. Amiodarone does not induce CYP3A4 metabolism of digoxin, and it is the amiodarone affecting digoxin levels, not the other way around.

Question 10

A 70-year-old male with persistent atrial fibrillation has been on a rate control strategy with diltiazem for several years. He remains symptomatic with exertional dyspnea and palpitations. His ventricular rate is 85 bpm at rest and 130 bpm with mild exertion. The decision is made to attempt a rhythm control strategy.

Prior to planned direct current cardioversion, which pharmacological management is an absolute prerequisite if the duration of his current AFib episode is unknown or greater than 48 hours?

Initiation of an antiarrhythmic drug like amiodarone for at least 4 weeks.
Administration of intravenous heparin to achieve an immediate therapeutic PTT.
Discontinuation of diltiazem to prevent post-cardioversion bradycardia.
At least 3 consecutive weeks of effective systemic anticoagulation. (correct answer)

Explanation: Cardioversion (either electrical or pharmacological) for AFib of >48 hours duration or unknown duration carries a risk of thromboembolism from dislodging a pre-existing left atrial appendage thrombus. To minimize this risk, guidelines mandate a period of effective systemic anticoagulation (e.g., with a DOAC or warfarin with INR 2-3) for at least 3 weeks before the procedure and for at least 4 weeks after. While IV heparin can be used for acute cardioversion after a transesophageal echocardiogram (TEE) rules out a thrombus, the standard outpatient approach requires weeks of oral therapy. Initiating an antiarrhythmic (A) may be done to improve success but is not the absolute prerequisite for safety. Discontinuing diltiazem (C) is not required and may be detrimental if cardioversion fails.

Question 11

Digoxin directly blocks calcium channels in the AV node, while metoprolol blocks sodium channels.
Digoxin increases vagal tone to the AV node, while metoprolol blocks sympathetic stimulation of the AV node. (correct answer)
Digoxin primarily acts by shortening the atrial refractory period, while metoprolol prolongs it.
Digoxin is a positive inotrope via Na+/K+ ATPase inhibition, while metoprolol is a negative chronotrope via beta-1 blockade.

Question 12

A patient with atrial fibrillation and chronic kidney disease (CrCl 40 mL/min) is being considered for rhythm control. Which agent's pharmacokinetics are most significantly altered in this setting, requiring careful dose adjustment or avoidance due to its primary reliance on renal elimination?

Amiodarone
Propafenone
Flecainide
Sotalol (correct answer)

Explanation: Sotalol is eliminated almost exclusively by the kidneys (>90% unchanged in urine). Its clearance is directly proportional to creatinine clearance. In patients with renal impairment, the drug's half-life is significantly prolonged, increasing the risk of accumulation and proarrhythmia (especially Torsades de Pointes). Therefore, sotalol requires significant dose reduction or avoidance in moderate to severe CKD. Dofetilide is also renally cleared and needs dose adjustment. Amiodarone is hepatically metabolized and does not require dose adjustment for renal dysfunction. Propafenone and flecainide are also primarily metabolized by the liver, although some dose reduction may be needed in severe renal failure.

Question 13

A patient stabilized on a rate control regimen with metoprolol for persistent atrial fibrillation remains symptomatic with fatigue. The decision is made to transition to a rhythm control strategy using amiodarone. The patient's baseline QTc is 440 ms.

After initiating amiodarone, what is the expected primary electrophysiological change on the surface ECG that reflects its dominant Class III mechanism of action?

Narrowing of the QRS complex
Shortening of the PR interval
Prolongation of the QT interval (correct answer)
Increase in the P wave amplitude

Explanation: Amiodarone's dominant effect is as a Class III agent, which involves blocking potassium channels responsible for repolarization. This action prolongs the action potential duration throughout the heart, which manifests on the ECG as a prolongation of the QT interval. This is the intended therapeutic effect for rhythm control but also the reason for the risk of Torsades de Pointes. Amiodarone can also slightly widen the QRS (Class I effect) and prolong the PR interval (Class II/IV effects), but QT prolongation is the most prominent and expected change reflecting its main mechanism. P wave amplitude is not directly affected.

Question 14

A 72-year-old female with persistent, symptomatic atrial fibrillation is being considered for a rhythm control strategy after failing rate control with metoprolol succinate. Her medical history is significant for a myocardial infarction 5 years ago, resulting in moderate left ventricular systolic dysfunction. An echocardiogram confirms an ejection fraction of 40% and a left atrial diameter of 4.8 cm.

Which of the following agents is the most appropriate choice for initiating long-term rhythm control in this patient?

Flecainide
Propafenone
Dofetilide (correct answer)
Sotalol

Explanation: This patient has structural heart disease, specifically coronary artery disease (post-MI) and systolic dysfunction (EF 40%). Class Ic antiarrhythmics, such as flecainide and propafenone, are contraindicated in patients with structural heart disease due to an increased risk of mortality (as shown in the CAST trial). Sotalol has both Class III and beta-blocking properties, but it can cause significant QT prolongation and Torsades de Pointes, and its negative inotropic effects may be detrimental in heart failure. Dofetilide and amiodarone are the preferred agents for rhythm control in patients with structural heart disease and heart failure. Between the given options, dofetilide is the most appropriate choice, although it requires inpatient initiation for QT monitoring.

Question 15

Which of the following agents is the most appropriate choice for initiating long-term rhythm control in this patient?

Flecainide
Propafenone
Dofetilide (correct answer)
Sotalol

Question 16

After initiating amiodarone, what is the expected primary electrophysiological change on the surface ECG that reflects its dominant Class III mechanism of action?

Narrowing of the QRS complex
Shortening of the PR interval
Prolongation of the QT interval (correct answer)
Increase in the P wave amplitude

Question 17

An 82-year-old male with a 5-year history of permanent atrial fibrillation is managed in an outpatient clinic. He is asymptomatic. His ventricular rate is well-controlled at 75 bpm on metoprolol succinate 50 mg daily. He is therapeutically anticoagulated with apixaban. His EF is 55%.

The patient's daughter asks if he should undergo a procedure to 'get his heart back in rhythm.' Which of the following is the strongest rationale for continuing with the current rate control strategy?

The risks of antiarrhythmic drug toxicity and cardioversion likely outweigh the benefits in an asymptomatic, elderly patient. (correct answer)
A rhythm control strategy would eliminate the need for long-term anticoagulation, but the procedural risks are too high.
Long-standing atrial fibrillation often leads to atrial remodeling, making rate control the only viable option.
Metoprolol provides superior stroke prevention compared to any rhythm control agent.

Explanation: For an elderly, asymptomatic patient with permanent AF and a well-controlled ventricular rate, a rate control strategy is generally preferred. Attempting rhythm control (e.g., with drugs or cardioversion) introduces risks such as proarrhythmia, organ toxicity from drugs like amiodarone, and procedural complications, which are unlikely to be offset by a significant improvement in quality of life or mortality. It is a common misconception that restoring sinus rhythm eliminates the need for anticoagulation; the decision to anticoagulate is based on stroke risk (CHA₂DS₂-VASc score). While atrial remodeling makes rhythm control more difficult, it is not impossible. Stroke prevention is achieved with anticoagulants, not rate control agents.

Question 18

The risks of antiarrhythmic drug toxicity and cardioversion likely outweigh the benefits in an asymptomatic, elderly patient. (correct answer)
A rhythm control strategy would eliminate the need for long-term anticoagulation, but the procedural risks are too high.
Long-standing atrial fibrillation often leads to atrial remodeling, making rate control the only viable option.
Metoprolol provides superior stroke prevention compared to any rhythm control agent.

Question 19

A 65-year-old male is maintained on long-term amiodarone for rhythm control of persistent atrial fibrillation. During a routine follow-up, he complains of fatigue, weight gain, and cold intolerance. His TSH is found to be 15 mU/L (reference range 0.4-4.0 mU/L).

This patient's symptoms are most likely a consequence of amiodarone's effect on thyroid function, which is primarily attributed to what property of the drug?

Its high iodine content and intrinsic effects on thyroid hormone synthesis and metabolism. (correct answer)
Its potent beta-adrenergic blocking properties that mask hyperthyroid symptoms.
Its ability to chelate essential minerals required for thyroid peroxidase activity.
Its inhibition of hepatic enzymes responsible for clearing reverse T3.

Explanation: Amiodarone is a structural analog of thyroid hormone and contains a large amount of iodine (about 37% by weight). It can cause both hypothyroidism (more common) and hyperthyroidism. Amiodarone-induced hypothyroidism can result from the Wolff-Chaikoff effect (iodine load inhibiting thyroid hormone synthesis) and by inhibiting the peripheral conversion of T4 to the more active T3. The patient's symptoms and elevated TSH are classic for hypothyroidism. While amiodarone has weak beta-blocking effects and affects hepatic enzymes, its profound impact on the thyroid is primarily due to its iodine content and direct effects on the gland.

Question 20

A 58-year-old male with hypertension and obstructive sleep apnea develops paroxysmal atrial fibrillation. He is started on lisinopril and encouraged to use his CPAP machine regularly.

This approach, which targets underlying conditions that promote the atrial fibrillation substrate, is best described by which of the following concepts in arrhythmia management?

Pill-in-the-pocket therapy
Rate control intensification
Upstream therapy (correct answer)
Hybrid therapy

Explanation: Upstream therapy refers to the use of non-antiarrhythmic drugs to target the underlying disease processes or risk factors that cause atrial remodeling and promote the development and perpetuation of atrial fibrillation. In this case, using an ACE inhibitor (lisinopril) to treat hypertension and managing obstructive sleep apnea with CPAP are examples of upstream therapy aimed at preventing the progression of the atrial substrate. Pill-in-the-pocket (A) is an acute rhythm control strategy. Rate control intensification (B) would involve adding or titrating beta-blockers or CCBs. Hybrid therapy (D) typically refers to a combination of pharmacological and procedural (e.g., ablation) approaches.